表紙
市場調查報告書
商品編碼
1000821

圖雷特氏綜合症(中樞神經系統):藥物開發中(2021年)

Tourette Syndrome (Central Nervous System) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 74 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

圖雷特氏綜合症(TS)是一種神經病,特徵是反覆性和刻板的非自願運動和發聲,稱為抽動。症狀包括眨眼和其他眼睛移動,皺眉,聳肩以及頭和肩抽筋。其他症狀包括觸摸鼻子,聞到東西,拍打手臂和跳動。年齡是病因之一,據說男性患這種疾病的可能性是女性的3至4倍。治療方法包括抗抑鬱藥,精神刺激藥和行為療法。

本報告調查了Tourette症候群(中樞神經系統)正在開發的藥物,並回顧了全球治療情況,管道療法,發展,管道產品藥物概況以及主要公司的評論,並提供了全面的信息,包括有關以下方面的最新消息:圖雷特氏綜合症的治療。

目錄

  • 簡介
  • 全球市場直接報告範圍
  • 圖雷特氏症候群-概述
  • 圖雷特氏症候群-治療的發展
  • 管道概述
  • 公司管道
  • 大學/機構管道
  • 公司正在開發的產品
  • 大學/機構正在開發的產品
  • Tourette的症候群治療評估
  • 按目標評估
  • 通過作用機制進行評估
  • 按管理途徑評估
  • 按分子類型評估
  • 圖雷特氏綜合症-參與治療開發的公司
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • 圖雷特氏症候群藥物簡介
  • Alpha-二氫丁苯那秦-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 貝伐洛爾-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 丁苯那秦-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 屈大麻酚+棕櫚□-藥物特徵
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 鹽酸Ecopipam藥品簡介
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 免疫球蛋白(人)-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • NOE-105-藥品檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • Sepranolone-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 拮抗DRD2的中樞神經系統和荷爾蒙紊亂的小分子-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 圖雷特的症候群休眠計劃
  • Tourette症候群停產的產品
  • Tourette症候群-產品開發里程碑
  • 精選新聞和新聞稿
  • 2021年2月11日:新的臨床前研究證實了Seplanolone可抑制Tourette症候群抽動
  • 2020年9月1日:Emalex生物科學2b期Tourette症候群的臨床試驗註冊達到里程碑
  • 2020年3月24日:Asarina Pharma計劃發佈過去的2b期PMDD數據
  • 2020年2月20日:Teva的丁丁苯那秦治療小兒Tourette綜合徵的臨床試驗失敗
  • 2019年8月28日:Emalex Biosciences獲得Ecopipam的FDA快速通道指定以治療Tourette綜合徵患者
  • 2019年8月14日:Emalex Biosciences宣佈第一名參加2期臨床試驗的患者,以評估Ecopipam片劑在治療Tourette綜合徵兒科患者中的療效和安全性
  • 2019年8月6日:Emalex Biosciences任命Atul R. Mahableshwarkar博士為藥物開發高級副總裁
  • 2018年6月11日:由Therapix Biosciences贊助的歐洲Tourette綜合徵研究協會2018年年會
  • 2018年4月9日:Therapy Biosciences宣佈耶魯大學Tourette綜合徵計劃2a期臨床試驗的主要結果
  • 2018年2月28日:Nuvelution Pharma宣佈開始接受AUSTEDO(R)的2/3期臨床試驗的患者入組,該臨床試驗用於治療小兒患者的Tourette綜合徵
  • 2018年2月7日:與FDA就治療生物科學中的圖雷特氏綜合症與THX-110完成IND之前的溝通:臨床開發計劃中的進展
  • 2017年12月4日:Therapy Biosciences宣佈完成耶魯大學Tourette綜合徵計劃2a期研究的註冊
  • 2017年10月11日:Nippon Chemiphar和SOM Biotech合作研究貝伐洛爾(Calvan)新罕見病的適應症
  • 2017年5月8日:Therapix Biosciences與漢諾威醫學院簽訂由研究人員發起的臨床試驗協議,以評估TXH-TS01在圖雷特氏綜合症患者中的療效
  • 2017年1月17日:宣佈Ecopipam治療Psyadon's小兒Tourette綜合徵的2期臨床試驗的陽性結果
  • 附錄
  • 調查方法
  • 調查範圍
  • 二次調查
  • 初步調查
  • 專家小組驗證
  • 聯繫我們
  • 免責聲明
目錄
Product Code: GMDHC12768IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • Tourette Syndrome - Drug Profiles
  • alpha-dihydrotetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevantolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • deutetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ecopipam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOE-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sepranolone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
  • Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
  • Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
  • Feb 20, 2020: Teva's deutetrabenazine fails in paediatric Tourette syndrome trials
  • Aug 28, 2019: Emalex Biosciences receives FDA Fast Track Designation for Ecopipam for the treatment of patients with Tourette Syndrome
  • Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
  • Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
  • Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
  • Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients
  • Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
  • Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
  • May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
  • Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
  • Tourette Syndrome - Pipeline by Asarina Pharma AB, 2021
  • Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2021
  • Tourette Syndrome - Pipeline by Evero Health Ltd, 2021
  • Tourette Syndrome - Pipeline by Noema Pharma AG, 2021
  • Tourette Syndrome - Pipeline by Octapharma AG, 2021
  • Tourette Syndrome - Pipeline by SOM Biotech SL, 2021
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Tourette Syndrome - Dormant Projects, 2021
  • Tourette Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021